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Introduction
The efficacy of stem/progenitor cells clinical application is currently
still limited by several knowledge gaps. In fact, the lack of a com-
plete understanding of molecular mechanisms driving progenitor
cell differentiation, the lack of well-defined criteria to identify the
best cell type for a given pathology and to select patients, still rep-
resent major bottlenecks in stem cells-based regenerative medi-
cine. In addition, the absence of validated, safe and reproducible
procedures for stem/progenitor cells production and quality test-
ing makes results from diverse clinical trials often incomparable.
This makes extremely difficult to raise valid and general conclu-
sions about efficacy of cells to regenerate organs affected by
degenerative disorders.
In the cardiovascular field, the use of adult bone marrow cells
(BMCs) having angiogenic activity and myocardial regeneration
GMP-based CD133 cells isolation maintains progenitor 
angiogenic properties and enhances standardization 
in cardiovascular cell therapy
Giuseppe Gaipa a, b, Manuela Tilenni c, Stefania Straino d, Ilaria Burba c, Germana Zaccagnini d,
Daniela Belotti a, Ettore Biagi a, e, Marco Valentini f, Paolo Perseghin a, Matteo Parma e, 
Cristiana Di Campli f, Andrea Biondi b, Maurizio C. Capogrossi d, Giulio Pompilio c, Maurizio Pesce c, *
a Laboratorio Interdipartimentale di Terapia Cellulare Stefano Verri, Azienda Ospedaliera San Gerardo, Monza, Milan, Italy
b Centro Ricerca M. Tettamanti, Clinica Pediatrica Università degli Studi di Milano Bicocca, 
Azienda Ospedaliera San Gerardo, Monza, Italy
c Laboratorio di Biologia Vascolare e Medicina Rigenerativa, Centro Cardiologico Monzino-IRCCS, Milan, Italy
d Laboratorio di Patologia Vascolare, Istituto Dermopatico dell’ Immacolata, IDI-IRCCS, Rome, Italy
e Dipartimento di Ematologia, Università degli studi di Milano Bicocca, Azienda Ospedaliera San Gerardo, Monza, Italy
f Biorep s.r.l., Milan, Italy
Received: December 23, 2008; Accepted: July 1, 2009
Abstract
The aim of the present study was to develop and validate a good manufacturing practice (GMP) compliant procedure for the prepara-
tion of bone marrow (BM) derived CD133 cells for cardiovascular repair. Starting from available laboratory protocols to purify CD133
cells from human cord blood, we implemented these procedures in a GMP facility and applied quality control conditions defining purity,
microbiological safety and vitality of CD133 cells. Validation of CD133 cells isolation and release process were performed according
to a two-step experimental program comprising release quality checking (step 1) as well as ‘proofs of principle’ of their phenotypic
integrity and biological function (step 2). This testing program was accomplished using in vitro culture assays and in vivo testing in an
immunosuppressed mouse model of hindlimb ischemia. These criteria and procedures were successfully applied to GMP production of
CD133 cells from the BM for an ongoing clinical trial of autologous stem cells administration into patients with ischemic cardiomy-
opathy. Our results show that GMP implementation of currently available protocols for CD133 cells selection is feasible and repro-
ducible, and enables the production of cells having a full biological potential according to the most recent quality requirements by
European Regulatory Agencies.
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potential has yielded promising results (reviewed in [1, 2]).
Several clinical trials have been performed worldwide and, today,
more than 1000 patients with acute and chronic cardiac
ischemia, or peripheral artery disease, have been treated using
autologous BMCs. The results obtained in trials with acute
myocardial infarction (MI) or ischemic heart failure patients have
been analysed in meta-analysis studies [3–7]. Although based
on different study selection criteria, these analyses were in
agreement that administration of autologous cells in the heart is
safe, and that it causes an improvement, although modest, in
primary clinical end-points such as ejection fraction, end-sys-
tolic volume and infarct scar size.
A possible explanation for the null or modest effect of BMCs
administration in patients may arise from the use of non-selected
cellular fractions [8]. In fact, it has been suggested that adminis-
tration of non-selected BMCs may have an antagonistic, ‘Janus-
like’, effect resulting from the secretion of cytokines having a pro-
vasculogenic, but also pro-inflammatory and pro-atherogenic
effects [9]. Thus, while BMCs injection has been reported to bet-
ter preserve heart function compared to other progenitor cells
types such as mesenchymal stem cells, skeletal myoblasts and
fibroblasts [10], the use of selected progenitors may prevent pos-
sible adverse consequences such as inflammatory and athero-
genic response (discussed in [11]).
Endothelial progenitors cells (EPCs) have been found in the
human umbilical cord blood (UCB), peripheral blood and the
adult bone marrow (BM) (reviewed in [12]). Recently, two distinct
EPCs populations have been identified and characterized, the
endothelial colony forming cells (ECFCs) (also named endothelial
outgrowing cells, OECs, or ‘late’ EPCs) that do not express the
CD45 pan-haematopoietic marker, and CD45CD133CD34-
derived EPCs that have been named colony forming unit-endothelial
cells (CFU-ECs or ‘early’ EPCs) [13–17]. The two cell types differ
in their clonogenic capacity as well as their ability to contribute 
to neo-vascularization process in vivo; while ECFCs have high
colonogenic activity and participate to formation of blood vessels
[16, 18], CFU-ECs have modest or null proliferation ability and
stimulate blood vessels formation in a paracrine way [18], by
secreting an array of pro-angiogenic and pro-inflammatory
cytokines [19].
A definitive consensus about the clinical use of one or the other
EPC type has not been reached. In fact, despite preclinical studies
have highlighted lineage distinctions and different biological prop-
erties of CFU-ECs and ECFCs, the CD34 and CD133 antigens
remain the reference markers to be used to isolate EPCs for clini-
cal trials, irrespective of their CD45 expression (discussed in
[20]). In fact, the benefits of isolated human CD34 and CD133
cells administration have been validated in MI [21–25] and hind
limb ischemia or cutaneous wounds [26–30] animal models.
Furthermore, compared to un-fractionated cells, purified CD34
and/or CD133 cells have a higher and dose-dependent angio-
genic effect and myocardial regeneration potential [8, 31] and a
higher selectivity for myocardial homing after intracoronary
administration into patients [32–34] compared to unselected cells.
Finally, significant clinical improvements by purified CD133 cells
administration have been reported in relatively small cohorts of
patients affected by acute or chronic myocardial ischemia
[35–40].
The use of purified stem cell populations in therapy needs a
careful evaluation concerning safety, quality and efficacy of cells.
To provide an answer to the growing need for improved standard-
ization of cell preparation protocols, the major regulatory agencies
worldwide, i.e. the US Food and Drug Administration (FDA) and
the European Medicines Agency (EMEA), have established regula-
tory frameworks to ensure high safety standards and biological
quality of cell-based medicinal products (CBMPs), that must com-
ply to good manufacturing practice (GMP) specifications.
In a recent study, F. Seeger and coworkers [41] have shown
that slight modifications in preparation protocols and the choice of
cell storage media have important consequences on the efficacy of
BMCs transplantation into ischemic tissues, by significantly affect-
ing their migratory ability and their in vivo angiogenic potential.
This example suggests that definition of clear and standardized
procedures to prepare stem cells for cardiovascular cell therapy
represents a key issue to obtain optimal clinical results.
The goal of the present study was to develop and test GMP-
compliant conditions to obtain purified CD133 cells (called here
CD133 CBMPs) to be used in patients with cardiac or lower limb
ischemia. We established standard operating procedures (SOPs)
to purify human Cord Blood (CB) CD133 cells using CliniMACS
and applied these procedures to obtain BM-derived CD133 cells
for an ongoing clinical trial in patients affected by chronic cardiac
ischemia. Here we thus describe a fully GMP-compliant CD133
CBMPs production and quality control process. We also provide a
demonstration that manipulated cells maintain a full biological
potency using in vitro and in vivo assays.
Materials and methods
Samples
UCB collection was performed after written approval by mothers. The age
of neonates ranged between 36 and 42 weeks of gestation. BM samples
were obtained from patients undergoing cardiac surgery upon approval of
the study by local ethical committee and Italian national regulatory agen-
cies (Istituto Superiore di Sanità, authorization no 63163-PRE.21–869, 
30-03-2006).
Isolation of CD133 CBMPs
Cord blood was recovered in ethylenediaminetetraacetic acid containing
bags immediately after delivery. Blood samples from at least three differ-
ent donors were pooled and used in each experiment. UCB mononuclear
cell fraction was obtained by Ficoll–Histopaque density gradient. Isolation
of CD133 cells was performed by CliniMACS™ (Miltenyi, Bergisch
Gladbach, Germany) system using the direct CD133 isolation kit (Miltenyi,
catalogue no. 177–01) according to manufacturer’s instructions. Briefly, after
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recovery from gradients, mononuclear cells were washed using Dulbecco’s
phosphate-buffered saline containing 1% (v/v) human serum albumin
(DPBS-HSA). This was followed by two centrifugations at 600  g for 
10 min. Cells were subsequently resuspended into 100 ml volume with
DPBS-HSA containing 7.5 ml of CliniMACS™ CD133 reagent (Miltenyi
Biotech) and 1.5 ml of human IgG and incubated for 45 min. at room
 temperature under gentle agitation. After two washing steps (550  g, 
10 min.), mononuclear cells were resuspended in 100 ml of DPBS-HSA
and thereafter loaded into a column into CliniMACS device, where CD133
cells were separated and collected. Experiments performed to assess KDR
expression in CD133 cells were performed with cells isolated from small
BM aliquots (5–7 ml) of patients undergoing heart surgery using
miniMACS™ device (Miltenyi) and the indirect CD133 cells isolation kit
(Miltenyi), according to manufacturer’s instructions.
GMP process and quality control (QC) testing
A detailed description of our GMP program and QC testing of CD133
CBMPs is described in the supplementary online section.
In vitro experiments
CD133 CBMPs transported from the cell factory were stored in different
solutions: saline containing 1 mg/ml human albumin, Stem Span (Stem
Cells Technologies, Vancouver, Canada) or X-VIVO-15 medium (Lonza,
Basel, Switzerland). Shortly after arrival, cells were counted. They were
seeded in Stem Span containing a cytokine mixture supplemented with
interleukin (IL)-3 and IL-6 (both at 20 ng/ml), Flt3-Ligand and Stem cell fac-
tor (both at 100 ng/ml) to allow cell proliferation. In these experiments cells
were seeded at 105/well in 96-well plates. After 5 days under these condi-
tions, cells were counted. To assess endothelial differentiation, CD133
CBMPs expanded for 5 days were seeded onto Fibronectin (Sigma-Aldrich,
St. Louis, MO, USA)-coated dishes using M199 medium (Gibco, Carlsbad,
CA, USA) supplemented with 20% FBS, 100 units/ml penicillin/
streptomycin and 2 mM L-Glutamine and cultured for 7 days [42]. After 
7 days in these differentiation-promoting conditions, cells were fixed with
4% paraformaldehyde (Sigma) for 20 min. and incubated overnight with 
2 g/ml of dioctadecyl-tetramethylindo-carbocyanine perchlorate (DiI)-
labelled acetylated LDL (DiIAcLDL; Biomedical Technologies, Firenze, Italy).
After washing with PBS, cells were stained with 40 g/ml of FITC-labelled
Lectin from Ulex europaeus I (Lectin UEA I; Sigma-Aldrich) for 1 hr. Nuclei
were stained with Hoechst 33258 (Sigma-Aldrich). For vWF immunofluo-
rescence, cells were fixed with 4% paraformaldehyde and permeabilized
using PBS containing 0.2% Triton-X 100 and 1% bovine serum albumin.
Anti-human vWF antibody (Chemicon, Billerica, MA, USA) was diluted at 
10 g/ml in the same medium. Cells were incubated with primary antibody
overnight at 4C and, following extensive washing, were incubated with
Alexa-488 conjugated anti-rabbit secondary antibody for 1 hr at room tem-
perature. Cells were observed under a Zeiss (Zeiss-Italy, Arese, Italy) Axio
Observer.Z1 fluorescence microscope equipped with Apotome image
deconvolution hardware. Immunophenotyping by flow cytometry was per-
formed as described in the online Supporting Information.
Cytokine quantification by multiplex analysis
Angiogenic cytokines expression in CFU-ECs obtained from BM-derived
CD133 CBMPs was measured by analyzing their concentration (expressed
as pg/ml/105 cells) in conditioned medium. M199 containing 20% FBS was
conditioned for 24 hrs. The concentration was measured by Bio-Plex 
Pro-Angiogenesis assay (Bio-Rad-Italy, Segrate, Italy). As a negative
 control the same, non-conditioned, medium was used.
In vivo experiments
Swiss CD1 male mice, 2 months old (Charles River, Italy), were used in this
study. Immunosuppression was performed by injecting cyclosporin-A 
(Cs-A) at 20 mg/kg weight for 2 days before, and daily after surgery, for
the entire period of the experiment. To produce hind limb ischemia, the left
femoral artery was excised with an electrocoagulator from its proximal ori-
gin as a branch of the external iliac artery till the bifurcation into saphenous
and popliteal arteries as described [43]. Mice were anesthetized with an
intra-peritoneal injection of 2.5% Avertin (Sigma) (100% Avertin: 10 g
2,2,2-tribromoethyl alcohol in 10 ml tert-amyl alcohol). Injection of CD133
CBMPs (105/animal) resuspended in saline solution (105 cells /50 l) was
performed at the time of surgery; 10 l of cell containing solution were
injected at five levels (from proximal to distal) into the adductor muscle,
along the femoral artery site after its removal. Laser Doppler Perfusion
Imaging (LDPI) was used to monitor tissue immediately after and at 7 and
14 days after surgery.
Histology and morphometric analysis
Anesthetized mice were perfused with saline solution containing 1000 U/ml
heparin (Roche Molecular Biochemical, Monza, Italy) followed by 10%
buffered formalin for 10 min. via the left ventricle at 100 mm Hg. Adductor
muscles were removed, fixed in formalin for 48 hrs and embedded in
paraffin (Bio-plast special; melting point 52–54C). Sections from each
sample were cut at a 3 m thickness and both capillary number and arte-
riole number were analysed as described [44, 45].
Statistical analysis
All data are expressed as mean  S.E.M.; 2-tailed unpaired Student’s t-test
was performed with GraphPad statistical software, and a probability value
of P  0.05 was considered statistically significant.
Results
From purification to quality control and certification
of CB CD133 CBMPs production procedure
Implementation of currently available laboratory procedures to
large scale GMP setting into the cell factory required appropriate
validations in order to: (1) establish detailed SOPs, (2) identify and
monitor critical steps during the production process and (3) define
final product release specifications. In order to develop SOPs for
CD133 cells isolation from human cord blood we used laboratory
protocols already established during our previous experience.
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Magnetic purification by CliniMACS was chosen as it is performed
with clinical grade reagents that are routinely used for purification
of haematopoietic stem cells in haematological transplantation
settings [46, 47], and because it was safely used in previous stud-
ies to produce CD133 cells for the treatment of patients with car-
diac ischemia [35, 38, 40].
The GMP-compliant CD133 CBMPs production process was
organized and accomplished according to the scheme presented
in Fig. 1. In this scheme, the QC testing actions, the locations of
each action and the responsibility of the actions at each step are
represented. Table 1 describes the tests, the methods according to
European Pharmacopeia and the product specifications that were
utilized to proceed with CD133 CBMPs lot certification and
release. Specifications were intended as threshold values to be
met for lot release. Figure 2 represents a typical example of flow
cytometric assessment of CD133 CBMP vitality and purity. To this
purpose a hierarchical gating strategy was followed; specifically,
cell purity was evaluated by first gating the CD45 cells and then
by determining the percentage of CD45/PI living cells, to which
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Fig. 1 Scheme representing the main actions that were performed during the validation procedure adopted in the present study. The locations, the QC
testing steps, and the main responsibilities are shown.
Test Method Specification
Purity
Flow cytometry 
(%CD133 cells) 	50%
Vitality
Flow cytometry (propidium
iodide staining)
	70%
Number of total
nucleated cells
Automated/manual cell 
counting 	10
6
Sterility
Sterility test (European
Pharmacopeia)
Negative
Mycoplasma
Cultural test (European
Pharmacopeia)
Negative
Endotoxin
Limulus amebocyte lysate test
(European Pharmacopeia)
0.5 EU/ml
Table 1 QC testing thresholds adopted for CD133 CBMP production
process under GMP conditions
J. Cell. Mol. Med. Vol 14, No 6B, 2010
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was finally applied the appropriate gate to identify CD133/CD34
cells. Results obtained by this testing are shown for each CB-
derived CD133 CBMPs lot in Table 2. It is to be noted that in all
these preparations, threshold values were successfully met.
Finally, as shown in Table 3, sterility, endotoxin and mycoplasma
tests were negative in all CD133 CBMPs lots preparation.
Altogether, these results show high reproducibility of the CD133
CBMPs production process under aseptic conditions.
Proof of principle of CB CD133 CBMPs biological
quality maintenance (1): in vitro experiments
A key issue to be addressed in the assessment of CBMPs quality
is, according to EMEA guidelines (Guideline on Human Cell-Based
Medicinal Products, doc. ref. emea/chmp/410869/2006), the
demonstration of ‘proofs of principle’ that CBMPs maintain a full
biological potential by appropriate ‘potency’ tests. This ensures
that the production process does not modify the ability of stem
cells to engraft in recipient tissues and that they maintain the
expected and desired regenerative effect.
We thus performed in vitro experiments according the
scheme shown in Fig. 3(A). Briefly, the cells were grown in cul-
ture with mitogenic cytokines [29] for a period of 5 days, after
which they were counted. After counting, cells were plated under
differentiation conditions to assess the formation of EPC (CFU-
EC) early colonies [15, 42, 48]. According to Seeger et al. [49],
the choice of the storage medium represents an important step
toward the optimization of cells to be transplanted. In our in vitro
assays, we tested different storage media in order to identify the
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Fig. 2 Example of vitality and phenotype testing of CD133 CBMP using four colour analysis by flow cytometry. (A) shows the initial gating that was
established on the scatter plot to identify cells having lymphocyte-like dimensions and complexity within the cellular population eluted from CliniMACS.
(B) shows the CD45 expression in cells gated on the basis of physical parameters in (A). This gating allowed to identify CD45 cells in this population.
(C) shows propidium iodide (PI) staining of the cells gated on the basis of CD45 expression. This gate allowed to discriminate between living (PI) 
and dead cells (PI) CD45 cells. (D) shows the expression of CD34 and CD133 in CD45 PI cells. This analysis shows that the majority of GMP-
produced CD133 cells shared the expression of the other stem cell marker CD34. (E) shows the physical paramenter of living CD45/CD133/CD34
cells isolated during the GMP production procedure. (F) illustrates the hierarchical gating strategy that was adopted in flow cytometry to hierarchically
identify living CD45/CD133/CD34 cells obtained by GMP-compliant selection procedure.
1624
condition that best maintains fully viable and biologically active
CD133 CBMPs for 18 hrs, i.e. the time which would elapse
between lot release and delivery of the cellular product at the
clinical centre.
As a storage medium during initial tests, we used saline solu-
tion supplemented with human albumin (HSA) at a 1% concentra-
tion (HSA 1%). CD133 CBMPs, stored overnight into HSA 1%
were cultured in serum free-medium containing mitogenic
cytokines (see ‘Materials and methods’). To our surprise, we
found that purified cells stored in this medium failed to proliferate
(Fig. 3B), likely due to cell damage during the overnight storage,
despite PI exclusion tests, performed before and after the
overnight period, did not indicate substantial cell death (not
shown). To better preserve CD133 CBMPs vitality, we thus set dif-
ferent storage strategies: we used X-VIVO-15 (X-VIVO) without
serum and saline solution containing different amounts of human
albumin (HSA 3.5%, HSA 5% and HSA 7.5%). The results 
(Fig. 3B, C) showed that CD133 CBMPs stored in these media had
a proliferation rate that was comparable to that shown by CB-
derived freshly isolated CD133cells under the same culture con-
ditions (Fig. 3C).
Both in animal models [21] and in patients [35, 39], CD133
cells have been found to have an angiogenic function. As a prelim-
inary in vitro screen for CD133 CBMPs angiogenic activity, we
tested formation of CFU-EC colonies by plating pre-expanded
CD133 CBMPs (stored into X-VIVO or HSA 7.5%) into fibronectin-
coated wells in high serum conditions [15, 42]. The results
showed the development of large cellular clusters taking up Ac-
LDL-DiI and stained with UEA-1 lectin [48] (Fig. 4), typically
resembling CFU-EC colonies [15].
© 2009 The Authors
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Lot # 1 2 3 4 5 6 7 8 9 10 Mean  S.D.
Viability
before 
isolation
89.76% 90.00% 95.00% 92.00% 95.90% 92.76% 84.80% 92.30% 92.00% 97.18%
92.17% 
3.53%
Viability
after 
isolation
78.70% 85.44% 80.00% 93.00% 91.00% 90.90% 93.54% 87.70% 98.48% 99.32%
89.81% 
6.96%
Number of
nucleated
cells
recovered
from
CliniMACS
4.32 
106
4.40 
106
1.65 
106
5.80 
106
4.20 
106
2.39 
106
11.20 
106
16.32 
106
2.11 
106
2.61 
106
5.50  106 
4.69  106
CD133
cells purity
66.90% 84.70% 82.70% 83.50% 82.50% 61.74% 90.40% 64.90% 77.97% 75.28%
77.06% 
9.59%
CD133
cells
recovery
67.30% 90.00% 58.87% 48.40% 58.90% 28.80% 90.00% 71.10% 65.00% 80.73%
65.91% 
18.83%
Table 2 Vitality (before and after isolation) of nucleated cells and CD133 cells. Purity and recovery for each of the 10 CD133 CBMP lots 
produced under GMP conditions
Lot # Sterility Endotoxin Mycoplasma
1 Neg 0.24 EU Neg
2 Neg 0.24 EU Neg
3 Neg 0.24 EU Neg
4 Neg 0.24 EU Neg
5 Neg 0.24 EU Neg
6 Neg 0.24 EU Neg
7 Neg 0.24 EU Neg
8 Neg 0.24 EU Neg
9 Neg 0.24 EU Neg
10 Neg 0.24 EU ND
Table 3 Sterility, endotoxin and mycoplasma screening in each of the
10 CD133 CBMP lots produced under GMP conditions
J. Cell. Mol. Med. Vol 14, No 6B, 2010
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Proof of principle of CB CD133 CBMP 
biological quality maintenance (2): Induction 
of angiogenesis in ischemic limbs
Previous studies have shown the ability of human CD34 and
CD133 cells to induce myocardial repair following infarction in
animal models of MI or injury [21–25]. Additionally, we and oth-
ers have shown the pro-vasculogenic effect of CD34 progenitor
cells using hind limb ischemia models in mice [26–29]. In the
present study the latter approach was used to demonstrate that
GMP-produced CD133 CBMPs maintain a pro-vasculogenic
potential and contribute to ischemic tissue repair, thus providing
direct evidence that GMP production process of these cells pre-
serves their biological activity.
The ability of CD133 CBMPs stored in X-VIVO and 7.5% HSA
to improve recovery of limb perfusion was evaluated by LDPI and
by capillaries and arterioles density determination. As shown in
Fig. 5(A), LDPI imaging showed that in all animals blood flow was
drastically reduced immediately after femoral artery dissection. In
saline-injected animals, a progressive recovery was detected
between day 7 and day 14 after femoral artery dissection. When
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Fig. 3 In vitro CB-derived
CD133 CBMPs proliferation.
(A) shows the experimental
scheme that was followed for
in vitro testing. After an initial 5
days in proliferation medium,
cells were counted to assess
growth. (B) shows the appear-
ance of cells after 5 days in
proliferation medium. Cells
that were stored in 1% HSA
containing saline proliferated
very poorly, while cells stored
in X-VIVO formed large clus-
ters of proliferating cells. (C)
shows the results of cell
counting at 5 days in prolifera-
tion medium. The fold expan-
sion of each cellular lot stored
under different storage condi-
tions is shown. The bar graph
indicates the comparison
between proliferation of GMP
produced CD133 CBMP and
freshly isolated CD133 cells.
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CD133 CBMPs were injected in the ischemic limbs, a significant
increase in perfusion ratio compared to saline-injected mice was
observed at the same time-points. Morphometric analysis was
performed on adductor muscle sections at day 14 after femoral
artery dissection. Both the capillary and the arterioles density 
(Fig. 5B and C, respectively) were significantly increased by
CD133 CBMP injection.
Translation of isolation procedures to BM 
samples for autologous transplantation in
patients affected by myocardial ischemia: release
quality control and in vitro proofs of principle
SOPs established to produce CB-derived CD133 CBMPs were
translated to production of clinical grade CD133 CBMPs from BM
of three patients undergoing a phase II clinical trial of CD133
cells intramyocardial administration, which has been recently
approved by Italian Regulatory Agency. This trial is currently being
carried at Centro Cardiologico Monzino.
Translation of GMP procedures to obtain BM-derived CD133
CBMPs from CB was not immediate and required suitable valida-
tion runs. In fact, differences in the stem cells sources may
cause (1) a different recovery of MNCs after Ficoll gradient cen-
trifugation and (2) a different purity of yielded cells due to differ-
ences in the CD133 expression level in BM compared to CB stem
cells. To address these issues we calculated the percentage of
MNCs loss after CB and BM Ficoll gradient centrifugation. As
shown in Table S1, a higher cellular loss was observed using BM
compared to CB. The difference in MNCs recovery was not sta-
tistically significant and a high variability was observed between
different samples. We also calculated the mean fluorescence
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Fig. 4 In vitro CD133 CBMPs differentiation. After 5 days in expansion medium, X-VIVO or 7.5% HSA saline solution stored cells were plated onto
fibronectin-coated dishes to promote the formation of CFU-EC EPC colonies. (A) shows the morphologic appearance of a CFU-EC cluster and the his-
tochemical detection by fluorescence microscopy of AC-LDL-DiI uptake (red fluorescence), UEA-1-FITC lectin (green fluorescence) staining and nuclear
staining (blue fluorescence) by Hoechst 33258.
J. Cell. Mol. Med. Vol 14, No 6B, 2010
1627
intensity (MFI) relative to CD133 expression in CB and BM stem
cells by flow cytometry; Fig. S1 shows a relatively lower MFI in BM
compared to CB stem cells; again comparison of the MFI values
did not reveal a statistically significant difference. Finally, to
assess whether lower MNCs recovery after Ficoll gradient cen-
trifugation and CD133 expression affect the quality of the final
products, we compared CB and BM CD133 CBMPs release qual-
ity parameters such as purity of CD133 cells (mean  S.D.:
73.52%  20.22% versus 77.06%  9.59%, BM versus CB; 
P 
 0.05, Student’s t-test), recovery of nucleated cells after
cliniMACSTM (mean  S.D.: 5.70  106  3.18  106 cells ver-
sus 5.50  106  4.69  106 cells BM versus CB; P 
 0.05,
Student’s t-test) and post-isolation vitality (mean  S.D.:
98.77%  1.02% versus 89.91%  6.96%, BM versus CB; P 

0.05, Student’s t-test). All these comparisons did not reveal sta-
tistically significant differences (see also Fig. 6, Tables 2 and 4),
showing that translation of SOPs developed for CB CD133 cells
to GMP production of BM-derived CD133 CBMPs produced sim-
ilar results to those obtained using CB.
A second step was to provide the suitable proofs of principle
that BM-derived CD133 CBMPs have a similar phenotype to that
of CB-CD133 cells. As an initial biological quality control test,
patients-derived CD133 cells first tested for the expression of
KDR antigen, an important marker defining progenitors having an
in vivo angiogenic activity [23, 28] (Fig. 7). The biological quality
of BM CD133 CBMPs was then functionally assessed by in vitro
tests that were performed according to the procedure established
for CB-derived CD133 shown in Fig. 3(A). In these experiments
it was found that, analogous to CB, BM-derived CD133 CBMPs
formed CFU-EC colonies (not shown). The endothelial-like pheno-
type of cells composing these colonies was confirmed by detec-
tion of the endothelial marker vWF by immunofluorescence 
(Fig. 8A) and by multicolour flow cytometry analysis, which
revealed that these cells were CD45 and expressed, although at
a lesser extent, CD31 and CD105 endothelial cells markers
(Fig. 8B and C). By contrast, the expression of CD144 and 
CD146 antigens, that are expressed in terminally differentiated
endothelial cells, was expressed in a minority of cells 
(Fig. 8B and C). Cells were also assayed for expression of mono-
cyte marker CD14, the pre-B/pre-T antigen CD48 and CD133 and
KDR stem cell markers (Fig. S2). Finally, to functionally charac-
terize the putative pro-angiogenic activity of BM-derived CD133
CBMPs, we tested the expression of angiogenic cytokines in 
CFU-EC conditioned media by multiplex analysis. Results showed
that these cells expressed HGF, IL-8, PDGF-BB and VEGF
cytokines (Fig. 8D).
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Fig. 5 In vivo potency test of CB-
derived CD133 CBMPs. (A) shows
the increase in perfusion ratio in
saline and CD133 CBMP-injected
limbs. The LDPI imaging sequences
show the increase in perfusion of the
same saline-injected or CD133
CBMP-injected mice at the three
times considered (T0, 7 and 14 days
after removing the femoral artery).
Plot shows the quantitative evalua-
tion of the limb perfusion ratio in
saline- (n  8) and CD133 CBMP-
(n  11) injected mice at the three
times considered. * indicates P 
0.05 by two ways unpaired t-test. (B)
shows the capillary density in
ischemic limbs injected with saline
solution (n 13) and CD133 CBMPs
(n  16). Insets show the capillaries
in injected adductor muscles. * indi-
cates P  0.05 by two ways
unpaired t-test. (C) shows the
increase in the number of arterioles
per histological section, as detected
by smooth muscle actin staining in
the same animals. Insets show the
arterioles stained by -actin anti-
body. * indicates P  0.05 by two
ways unpaired t-test.
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Test Method Specification Result (Mean ± S.D.)
Patient #1 Patient #2 Patient #3
Purity
Flow cytometry 
(% of CD133) 	50% 51.31% 90.87% 78.38% 73.52  20.22
Viability after isolation
Flow cytometry (propid-
ium iodide staining)
	70% 98.37% 99.93% 98.02% 98.77  1.02
Number of nucleated
cells recovered from
CliniMACS
Automated/manual cell
counting 	10
6 4.46  106 9.31  106 3.32  106 5.70  106 3.18  106
Sterility
Sterility test (European
Pharmacopeia)
Negative Negative Negative Negative -
Mycoplasma
Cultural test (European
Pharmacopeia)
Negative Negative Negative Negative -
Endotoxin
Limulus amebocyte
lysate test (European
Pharmacopeia)
0.5 EU/ml 0.24 EU/ml 0.24 EU/ml 0.24 EU/ml 0.24 EU/ml
Table 4 Translation of production procedures from CB to BM from three patients. QC testing showing the compliance to thresholds established
during step 1 validation procedure using CB
Fig. 6 Example of vitality and phenotype testing of CD133 CBMP from BM of one patient affected by chronic ischemic disease using four colour analy-
sis by flow cytometry. These cells were injected into the ischemic heart of the same patient. Gating hierarchy and panels description is as in Fig. 2.
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Discussion
Therapeutic use of EPCs has been suggested as a promising
approach to induce neo-vascularization in ischemic diseases
[50]. Despite a large number of preclinical reports describing
marked EPCs beneficial effect on ischemic tissues perfusion,
data obtained from meta-analyses of clinical trials have provided
evidence of only a modest clinical benefit [4–7, 51]. So far, the
reason for such a modest increase in heart function following
stem/progenitor cells administration is not clear. In fact, it is still
a matter of debate whether it may be related to a decreased bio-
logical function of cells obtained from patients with CVD risk fac-
tors (diabetes, hypercholesterolemia, hypertension) and/or to a
low survival/engraftment of the cells due to a hostile microenvi-
ronment such as that present into the ischemic myocardium
(discussed in [1]).
Different possible strategies to overcome the limited biologi-
cal function of EPCs from individuals at risk have been sug-
gested. A first option is provided by the possibility to use ex vivo
manipulation strategies such as culture in the presence of factors
that enhance ability of EPCs to migrate, proliferate/survive and
adhere [52–54] (also discussed in [41, 55, 56]). A second
 possibility, not necessarily alternative to the previous, is the use
of strategies that maximize CBMPs reproducibility, safety and
efficacy [49].
From GMP compliance to proofs of principle:
‘release’ and ‘potency’ validation levels for 
standardization of CBMPs production process 
for cardiovascular therapy
Today, GMP compliance requirement is one of the major tasks in
translational application of stem cells in cardiovascular disease. A
central component of GMP is the establishment of standard oper-
ational procedures for clinical grade manufacturing of cells, rang-
ing from the systematic checking and traceability of materials to
microbiological and efficacy validation of final products. Guidelines
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Fig. 7 Expression of VEGFR-
2/KDR receptor in BM-derived
CD133 obtained from patients. (A)
and (B) show the cellular popula-
tion that was gated in this analysis
and its CD133 expression. (C)
shows KDR expression in the
CD133 cells population gated in
(C). (D) shows the markers quan-
tification in three independent BM
cells preparations. In (B) and (C),
gating was established on the
basis of negative staining in the
presence of isotype control anti-
bodies conjugated to the respec-
tive fluorochromes.
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Fig. 8 In vitro testing of BM-
derived CD133 CBMP bio-
logical potency. (A) shows
immunofluorescence analy-
sis of human vWF in CFU-
ECs obtained from CD133
CBMPs. Left panel shows
the control staining that was
performed omitting the incu-
bation with the primary anti-
body, while right panel
shows the staining per-
formed in the presence of
primary and secondary anti-
body. (B) shows the expres-
sion of endothelial cell-spe-
cific markers in BM CD133
CBMPs-derived CFU-ECs by
flow cytometry. Each panel
indicates in the boxed areas
the specific staining for each
marker. Gating to calculate
percentage of marker posi-
tive cells was calculated on
negative control staining
with isotype antibodies con-
jugated with the respective
fluorochromes. The popula-
tion that was considered in
the marker analysis is indi-
cated as ‘physical gate’ in the
upper left panel. (C) shows
the quantification of specific
expression of each endothe-
lial marker expressed in
CFU-ECs. Results in the bar
graph are the mean  SE of
three independent experi-
ments. (D) shows quantifica-
tion of angiogenic cytokines
produced in the CFU-EC cul-
ture medium in a condition-
ing period of 24 hrs. The
expression of cytokines was
determined by Multiplex
assay.
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for GMP application in stem cell therapy have been established by
the International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use
(ICH). The European Community has adopted these guidelines to
introduce GMP regulations in the EU Member States. According to
the Directive 2006/86/EC ‘validation means establishing docu-
mented evidence that provides a high degree of assurance that a
specific process, piece of equipment or environment will consis-
tently produce a product meeting its predetermined specifications
and quality attributes; a process is validated to evaluate the per-
formance of a system with regard to its effectiveness based on
intended use’.
From these considerations CBMPs certification for use in
ischemic patients essentially requires a two-step validation pro-
gram (Fig. 9).
Step 1. During a preliminary step of GMP compliant CBMP
preparation procedure setup, tests are performed in order to
check for sterility and absence of mycoplasma and endotoxin con-
tamination and to set CBMPs purity/vitality thresholds. The execu-
tion of these experiments enabled us to establish criteria to ensure
the reproducibility of the purification procedure based on the
CliniMACS device (purity and vitality) and the safety of manipula-
tion procedures in sterility controls (mycoplasma, endotoxin and
sterility tests), to establish quality thresholds for the production
process of CD133 CBMPs as well as the lot-to-lot consistency. They
also led us to the important result of defining media (X-VIVO-15 or
7.5% HSA containing saline) for an optimal storage of the cells.
Step 2. A second but not less important validation step is the
assessment of CBMPs biological properties. These studies
demonstrate the CBMP potency (biological quality) in a suitable
model in vitro or in vivo. The demonstration provided by step 2 is
necessary to demonstrate that stem cells produced according to
the GMP-compliant procedure maintain the intended biological
activity which should be related to the expected clinical effect.
While step 1 validation tests are necessary at every CBMP lot
release, potency validation tests should not to be repeated. In fact,
once validated and suitably performed without amendments, the
procedure used for CBMPs preparation is recognized itself as a
compliant procedure to meet requirements needed for CBMP
human use. The experiments performed during this second phase
in the present study showed that the isolation procedure followed
by storage and transport under optimal conditions, allowed to
maintain a biological potency of CB CD133 cells similar to that
supposed for native cells (angiogenic potential) anticipated in sev-
eral preclinical studies.
Release and potency validation steps of BM
CD133 CBMPs for cardiovascular repair
The use of CD133 CBMPs in patients affected by myocardial
ischemia required translation to BM samples of isolation proce-
dures set using CB. Validation of procedures translated from CB to
BM firstly required appropriate testing in order to ensure that
product specification and minimal threshold parameters estab-
lished during CB isolation runs were met. This testing led us to
establish minimal starting quality thresholds (Table 5) such as (i )
a vitality higher than 90%, (ii ) a starting number of mononuclear
© 2009 The Authors
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mycoplasma and endotoxin contamination) to proceed with lot release. In the second step, the proof of principle of CD133 CBMP product potency was
demonstrated by suitable in vitro/in vivo experiments.
Fig. 9 The two-step validation
program necessary for the testing
of the CD133 CBMP production
process adopted in the present
study. The scheme illustrates the
activities that were accomplished
to achieve the certification of ‘clin-
ical grade’ CD133 CBMP for car-
diovascular use. During step 1
definition of SOPs was performed
followed by translation into the
GMP environment based on avail-
able laboratory protocols and
experience. During this step,
SOPs refinement was performed
in cell factory. This activity
enabled us to reach sufficient
reproducibility of the production
process by CLINI-MACS (purity
and vitality of CD133 cells) and
fulfil the pharmacopeia require-
ments (sterility, absence of
1632
cells higher than 5  109, (iii ) a total number of CD133 cells
higher than 15  106 and (iv ) execution of CD133 cells purifica-
tion process within 24 hrs after BM collection.
We then considered possible major deviations that may arise
from the different cellular composition of BM compared to CB and
possible differences in the expression levels of the CD133 stem
cell marker, which may affect recovery and purity of the final cel-
lular product. Comparison of MNCs loss after Ficoll centrifugation
and the analysis of MFI relative to CD133 expression in CB and BM
cells did not reveal statistically significant differences even if, as
shown in Fig. S1 and Table S1, for both parameters we noticed a
possible deviation that might reach statistically significance by
increasing the experimental replicates. On the other hand, it has to
be noted that purity, number of MNCs recovered from
cliniMACSTM and vitality of CD133 cells did not show the same
trend, suggesting that translation of isolation procedures from CB
to BM was feasible with a comparable efficiency. In this respect,
the adoption of improved strategies to minimize cellular loss dur-
ing Ficoll centrifugation is under study.
A final step required to assess the feasibility of BM-derived
CD133 CBMPs GMP production was to demonstrate the biolog-
ical potency of these cells by providing suitable proofs of 
principle. Due to the limited amounts of BM that we could use
for this purpose, we performed only in vitro tests aimed at
demonstrating the phenotype and the potential pro-angiogenic
function of these cells. These tests showed the endothelial-like
phenotype of CFU-ECs grown from these cells in culture and, in
line with existing literature, the mixed endothelial/monocytic/
myeloid phenotype of these cells [15, 16, 57–61]. Furthermore,
these cells produced, although at different levels, hepatocyte
growth factor (HGF), IL-8, platelet-derived growth factor-BB
(PDGF-BB) and vascular endothelial growth factor (VEGF)
cytokines. Altogether, these data suggest that BM-derived
CD133 CBMPs possess a pro-angiogenic paracrine activity.
In summary, our work shows that GMP implementation of 
currently available protocols to produce CD133 stem cells for
cardiovascular repair is feasible and that it maintains the innate
angiogenic properties of these cells. This work represents the first
example of protocol standardization that goes in the still unex-
plored direction of optimizing quality and enhancing reproducibility
of cellular products application into patients affected by ischemic
heart disease.
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Supporting Information
Additional Supporting Information may be found in the online
 version of this article:
Table S1 Comparison between the MNC loss using CB and BM
samples. Unpaired t-test was used to calculate statistical signifi-
cance.
Fig. S1 Comparison between the CD133 MFI in CB- and BM-
derived CD133 CBMP cells, as evaluated by flow cytometry. (A)
shows the histogram plots of CD133 fluorescence spectrum in
CB-derived (upper panel) and BM-derived (lower panel) CD133
CBMPs. Dotted lines indicate the putative mean fluorescence in
the two histograms. (B) shows quantification of CD133 MFI in CB
(n  10) and BM (n  3) CD133 CBMPs. It is evident the lower
MFI in BM-derived CD133 CBMPs. The difference did not reach
statistical significance (unpaired Student’s t-test; P  0.06; 
n  10 for CB and n  3 for BM).
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Test CB (our study) n  10 BM (our study) n  3 Suggested parameter for BM
Cell vitality (range) 84– 96% 93– 96% 
90%
Number of total nucleated cells (range) 1.0 – 3.4  109 5.1 – 5.9  109 
5  109
Number of total CD133 cells (range) 2.9 – 16.7  106 28.0 – 71.0  106 
15  106
Time delay from collection to processing 48 hrs 24 hrs 24 hrs
Table 5 Range of vitality, total number of nucleated cells, total number of CD133 cells and time delay from collection to GMP processing, as
recorded during validation runs using CB (n  10) and BM (n  3) in our study. These parameters are the basis to establish suggested minimal
thresholds that we advice to take into account to ensure feasibility of BM-derived CD133 CBMP GMP production process
J. Cell. Mol. Med. Vol 14, No 6B, 2010
1633
Fig. S2 Expression of myeloid (CD14), pre-B/Pre-T cells (CD48),
and endothelial progenitor cells (CD133, KDR) markers in CFU-
ECs obtained from CD133 CBMPs in culture as assessed by flow
cytometry analysis.
Please note: Wiley-Blackwell are not responsible for the content or
functionality of any supporting information supplied by the
authors. Any queries (other than missing material) should be
directed to the corresponding author for the article.
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